The Claim
In adults with type 2 diabetes, IDegLira provides equivalent postprandial glucose control compared to liraglutide monotherapy, despite a lower daily liraglutide dose (1.5 mg versus 1.8 mg), indicating that the addition of insulin degludec enhances the glucose-lowering effect of liraglutide.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with type 2 diabetes, a combination drug called IDegLira lowers blood sugar after meals just as effectively as liraglutide alone, even though it contains less liraglutide, because the added insulin degludec boosts liraglutide's effect.
See the scientific wording
In adults with type 2 diabetes, IDegLira achieves similar postprandial glucose control as liraglutide alone, despite delivering a lower daily dose of liraglutide (1.5 mg vs 1.8 mg), suggesting the addition of insulin degludec enhances the glucose-lowering effect of liraglutide.
A hormone that responds to food intake stimulates the pancreas to release more insulin, while also stopping the liver from releasing too much sugar; at the same time, a long-acting insulin provides steady background coverage, allowing the hormone to work more effectively with less of it needed.
What the research says
1 studyIDegLira, which has less liraglutide than liraglutide alone, still lowers blood sugar after meals just as well — because the added insulin helps liraglutide work better, so you don’t need as much of it.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.